{
  "url": "https://finance.yahoo.com/news/irlab-invitation-interim-report-q2-062000910.html",
  "authorsByline": "IRLAB Therapeutics",
  "articleId": "e868bb5f8a9143d29d58e3a130a80cc0",
  "source": {
    "domain": "finance.yahoo.com",
    "location": {
      "country": "us",
      "state": "CA",
      "county": "Santa Clara County",
      "city": "Sunnyvale",
      "coordinates": {
        "lat": 37.3688301,
        "lon": -122.036349
      }
    }
  },
  "imageUrl": "https://media.zenfs.com/en/accesswire.ca/f34fa3cd5f90a73ab729489d5817cd26",
  "country": "us",
  "language": "en",
  "pubDate": "2025-08-22T06:20:00+00:00",
  "addDate": "2025-08-22T06:36:14.693373+00:00",
  "refreshDate": "2025-08-22T06:36:14.693375+00:00",
  "score": 1.0,
  "title": "IRLAB: Invitation to The Interim Report for Q2 2025 Presentation and Webcast",
  "description": "GOTHENBURG, SE / ACCESS Newswire / August 22, 2025 / IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company discovering and developing novel treatments for Parkinson's disease, today announced that the company will hold a presentation in conjunction ...",
  "content": "GOTHENBURG, SE / ACCESS Newswire / August 22, 2025 / IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company discovering and developing novel treatments for Parkinson's disease, today announced that the company will hold a presentation in conjunction with the publication of the interim report for the period January - June 2025. The interim report will be published on Wednesday, August 27 at 07:00 CEST.\n\nThe presentation will be held on August 27, 2025, at 10:00CEST via digital webcast. Kristina Torfg\u00e5rd, CEO, Nicholas Waters, EVP and Head of R&D, and Viktor Siewertz, CFO, will comment the interim report. The presentation will be held in English and will be followed by a Q&A session.\n\nThe interim report and the presentation will be available on www.irlab.se , and the recorded version of the presentation will be available shortly afterward.\n\nIRLAB discovers and develops a portfolio of transformative treatments for all stages of Parkinson's disease. The company originates from Nobel Laureate Prof Arvid Carlsson's research group and the discovery of a link between brain neurotransmitter disorders and brain diseases. Mesdopetam (IRL790), under development for treating levodopa-induced dyskinesias, has completed Phase IIb and is in preparation for Phase III. Pirepemat (IRL752), currently in Phase IIb, is being evaluated for its effect on fall frequency in Parkinson's disease. IRL757, a compound being developed for the treatment of apathy in neurodegenerative disorders, is in Phase I. In addition, the company is developing two preclinical programs, IRL942 and IRL1117, towards Phase I studies. IRLAB's pipeline has been generated by the company's proprietary systems biology-based research platform Integrative Screening Process (ISP). Headquartered in Sweden, IRLAB is listed on Nasdaq Stockholm (IRLAB A). For more information, please visit www.irlab.se .\n\nIRLAB: Invitation to the interim report for Q2 2025 presentation and webcast",
  "medium": "Article",
  "links": [
    "https://pr.report/dj7n",
    "https://pr.report/dj7p",
    "https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/irlab-invitation-to-the-interim-report-for-q2-2025-presentation-and-w-1064123",
    "https://www.accessnewswire.com/",
    "https://pr.report/dj7o",
    "https://pr.report/dj7m"
  ],
  "labels": [],
  "claim": "",
  "verdict": "",
  "keywords": [
    {
      "name": "IRLAB A",
      "weight": 0.086947665
    },
    {
      "name": "Phase IIb",
      "weight": 0.08559482
    },
    {
      "name": "IRLAB Therapeutics AB",
      "weight": 0.08079085
    },
    {
      "name": "IRLAB",
      "weight": 0.07833569
    },
    {
      "name": "transformative treatments",
      "weight": 0.07610982
    },
    {
      "name": "novel treatments",
      "weight": 0.07581255
    },
    {
      "name": "Phase",
      "weight": 0.072463125
    },
    {
      "name": "brain diseases",
      "weight": 0.06977016
    },
    {
      "name": "Nasdaq Stockholm",
      "weight": 0.0685392
    },
    {
      "name": "brain neurotransmitter disorders",
      "weight": 0.06813085
    }
  ],
  "topics": [],
  "categories": [
    {
      "name": "Health"
    },
    {
      "name": "Finance"
    }
  ],
  "taxonomies": [
    {
      "name": "/News/Business News/Company News",
      "score": 0.97314453125
    },
    {
      "name": "/Business & Industrial/Pharmaceuticals & Biotech",
      "score": 0.947265625
    },
    {
      "name": "/Health/Health Foundations & Medical Research",
      "score": 0.615234375
    },
    {
      "name": "/News/Business News/Financial Markets News",
      "score": 0.50146484375
    },
    {
      "name": "/News/Health News",
      "score": 0.498046875
    },
    {
      "name": "/Finance/Investing/Stocks & Bonds",
      "score": 0.443603515625
    },
    {
      "name": "/Health/Pharmacy/Drugs & Medications",
      "score": 0.38916015625
    }
  ],
  "sentiment": {
    "positive": 0.26694003,
    "negative": 0.056213833,
    "neutral": 0.67684615
  },
  "summary": "IRLAB Therapeutics AB (Nasdaq Stockholm:IRL), a company discovering and developing novel treatments for Parkinson's disease, will hold a presentation in conjunction with the publication of the interim report for the period January - June 2025. The presentation will be held on August 27, 2025, at 10:00CEST via digital webcast. The interim report will be published on Wednesday, August 27 at 07:00 CEST. The company originates from Nobel Laureate Prof Arvid Carlsson's research group and is developing a portfolio of transformative treatments for all stages of Parkinson\u2019s disease.",
  "shortSummary": "IRLAB Therapeutics AB will present its interim report on Parkinson's disease in conjunction with a presentation on August 27, 2025, and a digital webcast will be available online.",
  "translation": "",
  "translatedTitle": "",
  "translatedDescription": "",
  "translatedSummary": "",
  "reprint": true,
  "reprintGroupId": "6e4ed7400c484491aa01f31fe672cbea",
  "places": [],
  "scraped_sources": [
    {
      "url": "https://pr.report/dj7n",
      "text": "IRLAB: Invitation to the interim report for Q2 2025 presentation and webcast\nGothenburg, Sweden, August 22, 2025 \u2013 IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson\u2019s disease, today announced that the company will hold a presentation in conjunction with the publication of the interim report for the period January \u2013 June 2025. The interim report will be published on Wednesday, August 27 at 07:00 CEST.\nRead More >IRLAB carries out SEK 136m rights issue\nISP \u2013 The proprietary technology platform\nIRLAB\u2019s unique and resource efficient research method, the Integrative Screening Process (ISP), generates the company\u2019s drug pipeline. This proprietary platform is built on a systems pharmacology discovery approach with an extensive, world unique, standardized database on CNS compounds and classes collected over 25 years.\nIRLAB\u2019s clinical phase II candidates\nMesdopetam (IRL790)\nIn development to treat levodopa-induced dyskinesia (LIDs), i.e. involuntary movements occurring upon long-term treatment with levodopa in Parkinson\u2019s disease.\nPirepemat (IRL752)\nIn development to treat impaired balance (postural dysfunction) leading to falls in Parkinson\u2019s disease.\nPresentation by Kristina Torfg\u00e5rd, CEO, at Aktiespararna\nPresentation by Kristina Torfg\u00e5rd, CEO, at Aktiespararna (in Swedish), held June 10, 2025.\nRead More >"
    },
    {
      "url": "https://pr.report/dj7o",
      "text": "IRLAB: Invitation to the interim report for Q2 2025 presentation and webcast\nGothenburg, Sweden, August 22, 2025 \u2013 IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson\u2019s disease, today announced that the company will hold a presentation in conjunction with the publication of the interim report for the period January \u2013 June 2025. The interim report will be published on Wednesday, August 27 at 07:00 CEST.\nRead More >IRLAB carries out SEK 136m rights issue\nISP \u2013 The proprietary technology platform\nIRLAB\u2019s unique and resource efficient research method, the Integrative Screening Process (ISP), generates the company\u2019s drug pipeline. This proprietary platform is built on a systems pharmacology discovery approach with an extensive, world unique, standardized database on CNS compounds and classes collected over 25 years.\nIRLAB\u2019s clinical phase II candidates\nMesdopetam (IRL790)\nIn development to treat levodopa-induced dyskinesia (LIDs), i.e. involuntary movements occurring upon long-term treatment with levodopa in Parkinson\u2019s disease.\nPirepemat (IRL752)\nIn development to treat impaired balance (postural dysfunction) leading to falls in Parkinson\u2019s disease.\nPresentation by Kristina Torfg\u00e5rd, CEO, at Aktiespararna\nPresentation by Kristina Torfg\u00e5rd, CEO, at Aktiespararna (in Swedish), held June 10, 2025.\nRead More >"
    }
  ],
  "argos_summary": "IRLAB Therapeutics AB will present its interim report for January - June 2025 on August 27, 2025, at 10:00 CEST via digital webcast. The report will be available on their website, along with a recorded version of the presentation. The company is focused on developing treatments for Parkinson's disease, with several candidates in various stages of clinical trials, including Mesdopetam and Pirepemat.",
  "argos_id": "ZUZ7GFNM2"
}